Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

Completed

• Conditions: Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment

• Registration Number: NCT05419102
• Lead Sponsor: North Dallas Dental Health

Brief Summary

The existing records of a private practice limited to the practice of periodontology were reviewed to locate patients who had been diagnosed with peri-implantitis (failing dental implant) and had been surgically treated utilizing enamel matrix derivative (Commercially available FDA product Emdogain sold by Straumann USA). Various clinical factors were gathered from the existing records. Some of the factors recorded were: retention of the implant, presence of bleeding, presence of further damage, and presence of inflammation. All patients had signed an informed consent for treatment and the anonymous use of their data for research purposes. All HIPA requirements were followed.

Detailed Description

See brief summary.

Study Timeline

• Study Start: 2022-04-01
• Primary Completion: 2022-05-15
• Status Verified: 2022-06
• Study Completion: 2022-06-06
• Study First Submitted: 2022-06-10
• Study First Submitted QC: 2022-06-10
• Last Update Submitted: 2022-06-10
• Study First Posted: 2022-06-15
• Last Update Posted: 2022-06-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• all adult patients of record who presented with existing peri-implantitis that was clinically deemed treatable (the implant was not considered hopeless.)

Exclusion Criteria

• none except for routine medical contraindications for periodontal surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
retention of the implant	0.71 to 6.4 years	Determine if the implant was still present at the time of reevaluation

Secondary Outcome Measures

Name	Time	Method
record the clinical condition of the implant at the time of reevaluation	0.71 to 6.4 years	Multiple standard measurements of the clinical condition of the implant were recorded at the time of reevaluation

Trial Locations

Locations (1)

North Dallas Dental Health; 🇺🇸 Dallas, Texas, United States